证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-035 黑龙江珍宝岛药业股份有限公司 第五届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司全资子公司哈尔滨珍宝制药有限公司（以下简称"哈珍宝"）申请银行 贷款展期并由公司为其提供担保事项符合公司整体经营和业务发展需要,符合公 司和全体股东的整体利益。本次担保风险可控,不存在损害公司股东尤其是中小 股东利益的情形，有利于公司整体生产经营的良性发展。董事会同意公司全资子 公司哈珍宝申请期限为一年的贷款展期业务，展期金额为不超过人民币 1.70 亿 元，由公司为哈珍宝本次贷款展期事项提供连带责任担保，并授权公司法定代表 人处理本次担保事项并签署相关协议。 表决结果：同意 5 票，反对 0 票，弃权 0 票。 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）披露的《黑龙 江珍宝岛药业股份有限公司关于为全资子公司银行贷款展期提供担保的公告》 （公告编号：临 2025-038 号）。 特此公告。 黑龙江珍宝岛药业股份有 ...

国新证券股份有限公司关于 黑龙江珍宝岛药业股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 国新证券股份有限公司（以下简称"国新证券"或"保荐机构"）作为黑龙 江珍宝岛药业股份有限公司（以下简称"珍宝岛"或"公司"）2020 年度非公开 发行 A 股股票的保荐机构，根据《中华人民共和国证券法》《证券发行上市保荐 业务管理办法》《上海证券交易所股票上市规则（2025 年 4 月修订）》《上海证券 交易所上市公司自律监管指引第 1 号——规范运作（2023 年 12 月修订）》《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修 订）》等有关法规和规范性文件的要求，对珍宝岛使用部分闲置募集资金暂时补 充流动资金的事项进行了审慎核查，核查意见如下： 一、募集资金的基本情况 1、募集资金到位及管理与存放情况 经中国证券监督管理委员会出具的《关于核准黑龙江珍宝岛药业股份有限公 司非公开发行股票的批复》（证监许可[2021]338 号）核准，珍宝岛非公开发行人 民币普通股（A 股）92,803,592 股，发行价格为 13.34 元/股，募集资金总额为人 民币 1,237,9 ...

重要内容提示： 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）归还募集资金 23,000 万元，并继续使用部分闲置募集资金临时补充流动资金总额不超过 30,000 万元，使用期限为自公司第五届董事会第二十二次会议和第五届监事会 第十八次会议审议通过之日起不超过 12 个月。 一、募集资金基本情况 1、募集资金到位及管理与存放情况 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-037 黑龙江珍宝岛药业股份有限公司 关于归还募集资金并继续使用部分闲置募集资金 暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经中国证券监督管理委员会出具的《关于核准黑龙江珍宝岛药业股份有限公 司非公开发行股票的批复》（证监许可[2021]338 号）核准，公司非公开发行人 民币普通股（A 股）92,803,592 股，发行价格为 13.34 元/股，募集资金总额为 人民币 1,237,999,917.28 元,扣除本次发行费用人民币 20,759,785.06 元（不含 税）且不包括人民币普通股（A 股） ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-038 黑龙江珍宝岛药业股份有限公司 关于为全资子公司银行贷款展期提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称：哈尔滨珍宝制药有限公司（以下简称"哈珍宝"），系黑龙 江珍宝岛药业股份有限公司（以下简称"公司"）的全资子公司。 ●本次担保金额为不超过人民币 1.70 亿元，截至公告披露日，公司已实际 为哈珍宝提供的担保余额为人民币 9.21 亿元（含本次担保）。 ●截至本公告披露日，公司实际对外担保总额人民币 16.01 亿元（含本次担 保），全部是公司对全资子公司进行的担保。 ●本次担保无反担保。 ●公司无对外担保逾期的情况。 公司全资子公司哈珍宝于 2024 年 5 月 15 日向哈尔滨联合农村商业银行股份 有限公司呼兰支行（以下简称"哈联合农村商业银行"）申请 1.70 亿元人民币贷 款，贷款期限为 12 个月，公司为哈珍宝上述贷款事项提供连带责任保证担保。 （具体内容详见公司于 2024 年 5 月 16 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-034 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 二、控股股东可交换公司债券本次换股价格调整情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"） 收到控股股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达 集团 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第 一期可交债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 4 月 11 日完成第一期可交债的发行。本 期可交债简称"23 创 01EB"，债券代码"137171"，发行规模 9.1 亿元，债券期 限 3 年。具体内容详见公司于 2023 年 4 月 12 日在上海证券交易所网站披露的临 2023-019 号公告。 根据《黑龙江创达集团有限公司 2023 年面向专业投资者非公开发行可交换 公司债券（第 ...

Core Viewpoint - The traditional Chinese medicine industry in China is rapidly developing, supported by national policies, with Zhenbaodao (603567.SH) emerging as a leading enterprise in the field, demonstrating stable performance and growth in its financial metrics [1][2][9]. Financial Performance - In 2024, Zhenbaodao achieved an operating income of 2.704 billion yuan and a net profit of 438 million yuan, with the core pharmaceutical industrial revenue reaching 2.376 billion yuan, reflecting a year-on-year growth of 20.23% [1][2][3]. - As of the end of 2024, the company's total assets amounted to 12.713 billion yuan, an increase of 1.98% from the beginning of the year, while the net assets reached 7.801 billion yuan, growing by 3.34% [2][3]. Industry Context - The pharmaceutical manufacturing sector is showing strong resilience amid structural adjustments, with a reported increase of 3.4% in the added value of large-scale pharmaceutical industries in 2024 [2]. - The overall revenue for large-scale pharmaceutical enterprises reached 29.7627 billion yuan, with profits totaling 4.0509 billion yuan, indicating a profit growth rate that outpaces the national industrial average by 2.4 percentage points [2]. Business Operations - Zhenbaodao's pharmaceutical industrial segment is its core business, contributing nearly 90% to its total revenue, with robust manufacturing capabilities across multiple production bases [3]. - The company has established a diverse product portfolio, including raw materials, chemical preparations, traditional Chinese medicine preparations, and biological preparations, supported by ongoing research and development [3]. Innovation and Development - Zhenbaodao is actively fostering new productive forces in the pharmaceutical industry through technological breakthroughs and innovative resource allocation, focusing on the development of innovative and generic drugs [4][5]. - The company has established partnerships with renowned universities and research institutions to enhance the quality standards of traditional Chinese medicine injections and other significant clinical research projects [4]. Social Responsibility and Industry Impact - Zhenbaodao emphasizes its social responsibility as a core strategy, contributing to public health and societal value creation, particularly in the context of increasing chronic disease treatment demands [7][8]. - The company has engaged in various social welfare initiatives, supporting education, culture, and health, thereby enhancing its brand value and long-term growth potential [8]. Recognition and Future Outlook - Zhenbaodao has received numerous accolades, including being listed among the top 100 pharmaceutical companies in China and recognized for its contributions to social responsibility and digital transformation [8][9]. - The ongoing policy support for traditional Chinese medicine is expected to further drive market growth, with Zhenbaodao positioned to leverage these opportunities through innovation and social responsibility [9].

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-033 黑龙江珍宝岛药业股份有限公司 关于参加 2025 年黑龙江辖区上市公司投资者网上 集体接待日活动暨 2024 年度及 2025 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 投资者可于 2025 年 5 月 9 日（星期五）至 5 月 13 日（星期二）16:00 前登录"全景路演"网站首页点击"互动平台"栏目或以电子邮件的形式发送至 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）董事会办公室邮箱 （zbddsh@zbdzy.com），公司将在信息披露允许的范围内就投资者普遍关注的问 题进行回答。 公司已于 2025 年 4 月 30 日在上海证券交易所网站（www.sse.com.cn）披露 了公司 2024 年年度报告以及 2025 年第一季度报告，为便于广大投资者更全面深 入地了解公司财务状况与经营情况，公司将参加由黑龙江省上市公司协会与深圳 市全景网络有限公司联合举办的"2025 年黑龙江辖区上市公司投资者集体接 ...

Core Insights - The company achieved a revenue of 2.704 billion yuan and a net profit of 438 million yuan for the fiscal year 2024, with a notable 20.23% year-on-year growth in pharmaceutical industrial revenue, highlighting its strategic depth and growth resilience [1] - The company is transitioning from a traditional pharmaceutical enterprise to a leader in the pharmaceutical health ecosystem, supported by a comprehensive industrial chain [1] Group 1: Innovation and R&D - The company focuses on innovative drug and generic drug development, establishing three incubation industrial parks for traditional Chinese medicine, chemical drugs, and biological drugs [2] - Collaborations with renowned universities and research institutions are in place to enhance the quality standards of traditional Chinese medicine injections and conduct significant clinical research projects [2] - The company has successfully launched 10 generic drugs and has 14 traditional Chinese medicine products included in the national centralized procurement [2] Group 2: Smart Manufacturing and Digital Transformation - The company is committed to building a smart factory for traditional Chinese medicine, integrating digital technologies into pharmaceutical manufacturing [3] - The implementation of AI visual inspection technology has improved production efficiency and quality by identifying defects in real-time [3] - The company was recognized as a "2024 Intelligent Manufacturing Demonstration Factory" due to its achievements in smart manufacturing [3] Group 3: Supply Chain and Market Strategy - The company enhances its core competitiveness in the source of medicinal materials through a "six unification" operational model, extending its industrial chain across major traditional Chinese medicine production areas [4] - Strategic negotiations for industry fund projects in regions like Chongqing are underway to promote high-quality development in the national traditional Chinese medicine industry [4] - The company has integrated online and offline trading systems for medicinal materials, fostering a new circulation model [4] Group 4: Future Outlook - The company's comprehensive industrial chain advantages are evident in its resource integration and collaborative capabilities, positioning it as a key player in the transformation of the Chinese pharmaceutical industry [5] - With ongoing regional project collaborations and innovative drug pipelines, the company is expected to provide quality investment opportunities in the capital market [5]

Core Viewpoint - Zhenbaojiao (603567.SH) demonstrates robust growth in 2024, with a notable 20.23% year-on-year increase in revenue, particularly in its pharmaceutical manufacturing core business, supported by a diversified product matrix and an innovative R&D system [1] Group 1: Business Performance - The company has established a product matrix covering major categories such as cardiovascular, antiviral, respiratory, and pediatric medicine, showcasing its strength in traditional Chinese medicine [1][2] - In 2024, Zhenbaojiao aims to seize market opportunities by deepening its presence in various terminal markets and gradually building a core product group focused on key therapeutic areas [2] Group 2: Market Potential - The market scale for Zhenbaojiao's core products is significant, with annual market sizes exceeding 100 billion yuan for both cardiovascular and respiratory traditional Chinese medicine [3] - Zhenbaojiao's products, such as Xuefu Zhuyu Capsule and Shuxuening Injection, rank highly in market share within their respective therapeutic areas, indicating strong competitive positioning [3] Group 3: Innovation and R&D - The company is committed to enhancing product competitiveness through R&D and acquisitions, focusing on expanding its product line and improving product quality [4] - Zhenbaojiao is actively engaged in research and re-evaluation of existing products, including clinical efficacy and safety assessments, and is advancing innovative drug projects [4] Group 4: Mergers and Acquisitions - The company has completed the acquisition of 23 products, including Dan Ning Pian and An Gong Niu Huang Wan, to enrich its product pipeline and enhance market competitiveness [5] Group 5: Marketing and Distribution - Zhenbaojiao has established a comprehensive marketing network across over 30 provinces in China, focusing on cardiovascular and respiratory diseases while expanding into pediatric and digestive health markets [7] - The company is actively participating in centralized procurement projects, having successfully selected 14 core product specifications for national and provincial procurement initiatives [7] Group 6: Trade and Strategic Development - The company is optimizing its national trading strategy for traditional Chinese medicine, establishing a network of offices in major production areas to enhance supply chain efficiency [8] - Zhenbaojiao aims to leverage its advantages in market share, R&D innovation, and marketing systems to solidify its leading position in the traditional Chinese medicine industry [8]

Core Insights - The company reported a revenue of 2.704 billion yuan and a net profit attributable to shareholders of 438 million yuan for the year 2024, with a 20.23% year-on-year growth in pharmaceutical industrial revenue driven by optimized marketing strategies [1] Group 1: Financial Performance - In 2024, the company achieved a revenue of 2.704 billion yuan and a net profit of 438 million yuan [1] - The pharmaceutical industrial revenue grew by 20.23% year-on-year due to enhanced marketing model adjustments [1] Group 2: Market Participation and Product Offerings - The company actively participated in national drug procurement projects, securing 14 core specifications in the third batch of national traditional Chinese medicine procurement [1] - A total of 86 products from the company were included in the latest national medical insurance directory, with 35 classified as Category A and 51 as Category B [1] Group 3: Marketing Strategy and Network Development - The company has established a nationwide marketing network covering over 6,000 medical institutions across more than 30 provinces, integrating a full-chain service system from urban public hospitals to retail terminals [3] - The marketing strategy focuses on cardiovascular and respiratory diseases while expanding into pediatric and digestive health markets, utilizing diverse sales channels and marketing strategies to drive growth [2][3] - The company emphasizes a comprehensive marketing approach with a focus on sales capability enhancement across different business units, targeting commercial sales, medical terminal markets, and retail pharmacies [3]